



**LKT Laboratories, Inc.**

**SU-9516**

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

## Product Information

**Product ID** S800000

**CAS No.** 377090-84-1

**Chemical Name**

**Synonym** SU9516

**Formula** C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>

**Formula Wt.** 241.25

**Melting Point**


Purity ≥98%

**Solubility**

**Store Temp** 4°C

**Ship Temp** Ambient

**Description** SU-9516 is an inhibitor of cyclin-dependent kinase (CDK), with selectivity for CDK2. It induces apoptosis in colon carcinoma cells. In leukemic cells, it downregulates Mcl-1, an antiapoptotic protein, leading to mitochondrial injury and cell death.



## Pricing and Availability

**Bulk quantities available upon request**

<b>Product ID</b>	<b>Size</b>	<b>List Price</b>
S800000	5 mg	\$95.00
S800000	25 mg	\$275.00
S800000	100 mg	\$485.00

**References** Oprchal M., Salisbury J., et al. Inhibition of Cdk2 kinase activity selectively targets the CD44<sup>+</sup>/CD24<sup>-</sup>/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. *Int J Oncol.* 45(3):1193-9 (2014). PMID:24970653.

Lane M., Yu B., et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. *Cancer Res.* 61 (16):6170-7 (2001). PMID: 11507069.

Gao N., Kramer L., et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. *Mol Pharmacol.* 70(2):645-55 (2006). PMID: 16672643.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.